Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOS: Roflumilast in COPD with Salmeterol
NCT00313209Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2006
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Roflumilast with Placebo (2 arms). Primary endpoint: Pre-bronchodilator Forced Expiratory Volume in First Second at 24 weeks. Started Apr 2006; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00313209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00313209.